ライフサイエンスコーパス: pancreas transplantation

1 isky and technically challenging whole-organ pancreas transplantation.

2 readmissions after kidney, liver, and kidney-pancreas transplantation.

3 ainage should be the procedure of choice for pancreas transplantation.

4 safe and effective after simultaneous kidney-pancreas transplantation.

5 l has historically exceeded that of solitary pancreas transplantation.

6 plied the two-layer method to clinical whole-pancreas transplantation.

7 3 beyond 3 months after simultaneous kidney-pancreas transplantation.

8 e of surgery may have a protective effect in pancreas transplantation.

9 iteria in order to expand the donor pool for pancreas transplantation.

10 obstacle when deciding whether to recommend pancreas transplantation.

11 ular complications after combined kidney and pancreas transplantation.

12 metabolism are of particular significance in pancreas transplantation.

13 py for metabolic control) underwent solitary pancreas transplantation.

14 when compared with the consistent success of pancreas transplantation.

15 ost disease (GVHD) after simultaneous kidney-pancreas transplantation.

16 ients with significant CAD to safely undergo pancreas transplantation.

17 sulin-dependent diabetics were evaluated for pancreas transplantation.

18 n a cohort of diabetic patients referred for pancreas transplantation.

19 stula, and arterioenteric fistula related to pancreas transplantation.

20 gnosing rejection or graft dysfunction after pancreas transplantation.

21 isone therapy are recognized consequences of pancreas transplantation.

22 long-term risk-benefit ratio of FK506 after pancreas transplantation.

23 ted a mean of 14.5 months (range 1-81) after pancreas transplantation.

24 d glucose metabolism remained abnormal after pancreas transplantation.

25 observed in glycemic levels after successful pancreas transplantation.

26 D-BMI of 30 kg/m to decline donor offers for pancreas transplantation.

27 iding the choice for prophylactic therapy in pancreas transplantation.

28 have a significant impact on the success of pancreas transplantation.

29 the role of SRL on native kidney function in pancreas transplantation.

30 ther laparoscopy can reduce the morbidity of pancreas transplantation.

31 lso be the case in a highly complex field as pancreas transplantation.

32 most common cause of early graft loss after pancreas transplantation.

33 eexploration was defined as within 1 week of pancreas transplantation.

34 d to an increasing number of indications for pancreas transplantation.

35 d whether NG decompression is necessary post pancreas transplantation.

36 ased immunosuppression has been effective in pancreas transplantation.

37 ophylaxis of CMV disease after kidney and/or pancreas transplantation.

38 We present two cases of acute GVHD following pancreas transplantation.

39 rmation, have been well documented following pancreas transplantation.

40 bstruction is an uncommon complication after pancreas transplantation.

41 phan-ketoglutarate (HTK) compared with UW in pancreas transplantation.

42 ype 1 diabetes mellitus underwent successful pancreas transplantation (108 kidney/pancreas transplant

43 in diabetic patients awaiting kidney and/or pancreas transplantation; (2) using the two radionuclide

44 nine models of the anatomical alterations of pancreas transplantation: 70% partial pancreatectomy (PP

45 s-kidney transplantation (SPK); 44 underwent pancreas transplantation after previous kidney transplan

46 Pancreas transplantation aims to restore physiologic nor

47 neous pancreas-kidney transplantation (SPK), pancreas transplantation alone (PTA), and pancreas after

48 dney transplantation (PAK); and 15 underwent pancreas transplantation alone (PTA).

49 Of the simultaneous pancreas and kidney, pancreas transplantation alone, and PAK transplant recip

50 RESULTS.: Simultaneous pancreas and kidney, pancreas transplantation alone, and pancreas after kidne

51 pancreas after kidney transplantation, and 8 pancreas transplantations alone.

52 Kidney-pancreas transplantation alters the diabetic milieu; yet

53 to examine de novo HLA antibodies following pancreas transplantation and clearly defines a high-risk

54 CEUS yields useful information after pancreas transplantation and has been proven a sensitive

55 he TLM of pancreas preservation before whole-pancreas transplantation and islet isolation show promis

56 afe and effective long-term primary agent in pancreas transplantation and provides excellent long-ter

57 Pancreas transplantation and the infusion of cadaveric i

58 cessful pancreas transplantation (108 kidney/pancreas transplantation) and another 28 patients with t

59 ng 18 HNF1B patients receiving SKT or kidney-pancreas transplantation, and in vitro experiments inclu

60 GVHD is a rare, often fatal, complication of pancreas transplantation, and its presentation appears t

61 e first year after kidney, heart, liver, and pancreas transplantation, and they could be associated w

62 ical complications after combined kidney and pancreas transplantation are a major source of morbidity

63 Patient and graft survival after pancreas transplantation are superior in higher volume c

64 An overview of 30 years of pancreas transplantation at a high volume center.

65 ods A cohort of adult patients who underwent pancreas transplantation at a tertiary institution over

66 leted of the results and complications after pancreas transplantation at one institution.

67 compared outcomes of 153 patients undergoing pancreas transplantation at our institution over a 3.5-y

68 donors and 431 recipients who had undergone pancreas transplantation at the Oxford Transplant Centre

69 enging in the setting of simultaneous kidney-pancreas transplantation, because a reduction in immunos

70 Clinical pancreas transplantation began at the University of Minn

71 apy provides effective immunosuppression for pancreas transplantation, but the optimal use of this dr

72 induction of immunsuppression for kidney and pancreas transplantation, but the two agents have not be

73 e of this study is to analyze the outcome of pancreas transplantation by using a single dose of 30 mg

74 ney transplantation (SKT) or combined kidney-pancreas transplantation can be considered.

75 Pancreas transplantation can be very challenging in the

76 Combined kidney-pancreas transplantation (CKPT) with its associated eugl

77 Successful pancreas transplantation corrects abnormal glucose metab

78 y larger series, laparoscopic robot-assisted pancreas transplantation could become a new option for d

79 al complications are a major disincentive to pancreas transplantation, despite the undisputed benefit

80 5-year pancreas graft survival rate, 29.7%), pancreas transplantation evolved during the second decad

81 The patients underwent isolated pancreas transplantation, following which, we have been

82 te mofetil (MMF) has been used in kidney and pancreas transplantation for almost 10 years.

83 Patients should rarely be excluded from pancreas transplantation for cardiac causes.

84 However, solitary pancreas transplantation for nonuremic patients with IDD

85 All patients undergoing pancreas transplantation from 2003 to 2010 were enrolled

86 eports the comparative short-term results of pancreas transplantation from donors after circulatory d

87 All consecutive pancreas transplantations from January 2008 until Decemb

88 Solitary pancreas transplantation has become a viable alternative

89 Pancreas transplantation has become the therapy of choic

90 A new surgical technique of pancreas transplantation has been developed with portal

91 Pancreas transplantation has been shown to fully restore

92 along with tacrolimus for > or =1 year after pancreas transplantation has not been studied in a large

93 ilure on hypertension by combined kidney and pancreas transplantation has not been studied.

94 Sirolimus (SRL) rescue in kidney-pancreas transplantation has not been well described.

95 ng-term safety and efficacy of tacrolimus in pancreas transplantation has not yet been demonstrated.

96 During the last 32 years, many problems in pancreas transplantation have been overcome and it may c

97 In conclusion, patients after pancreas transplantation have normal basal FFA turnover

98 %), nine IDDM patients after combined kidney-pancreas transplantation (HbA1c 5.8%), seven patients wi

99 tients with nephropathy before kidney and/or pancreas transplantation; however, controversy exists re

100 Solitary pancreas transplantation (ie, pancreas alone or pancreas

101 studies uniquely demonstrate that successful pancreas transplantation improves epinephrine response a

102 d pancreas graft survivals after 30 years of pancreas transplantation in a high volume center.

103 We report successful combined liver-pancreas transplantation in a patient with primary scler

104 designed to evaluate the results of solitary pancreas transplantation in a protocol that uses the new

105 o induce recurrent autoimmune diabetes after pancreas transplantation in mice.

106 These results question the safety of pancreas transplantation in obese patients and suggest t

107 We report herein the results of pancreas transplantation in patients receiving primary t

108 zumab and rATG induction in adult kidney and pancreas transplantation in patients treated with simila

109 rsy persists over the safety and efficacy of pancreas transplantation in patients with insulin-depend

110 To evaluate the risks of pregnancy after pancreas transplantation in the cyclosporine era, we sur

111 ere are limited data on how kidney or kidney-pancreas transplantation influence continuous autonomic

112 Pancreas transplantation involves anatomical changes tha

113 rocesses that support optimal outcomes after pancreas transplantation irrespective of center volume.

114 Pancreas transplantation is a controversial form of ther

115 Combined liver-pancreas transplantation is a relatively uncommon proced

116 Simultaneous kidney pancreas transplantation is a safe and effective method

117 Pancreas transplantation is a successful procedure with

118 Pancreas transplantation is a successful treatment for a

119 If pancreas transplantation is a validated alternative for

120 Using current DCD criteria, pancreas transplantation is a viable alternative to DBD

121 This multicenter survey shows that FK506 in pancreas transplantation is associated with (1) a low ra

122 l modifications or bariatric surgery, before pancreas transplantation is considered.

123 beta cell replacement via islet or pancreas transplantation is currently the only approach

124 ies to assess the hypothesis that successful pancreas transplantation is efficacious in normalizing e

125 The combination of MMF and tacrolimus after pancreas transplantation is highly effective and safe.

126 The most common cause of morbidity after pancreas transplantation is infection, particularly recu

127 The clinical success of pancreas transplantation is limited by the difficulty in

128 ss index on graft and patient survival after pancreas transplantation is not well known.

129 Pancreas transplantation is performed at relatively few

130 d the experience of alemtuzumab induction in pancreas transplantation is still limited.

131 Graft thrombosis following pancreas transplantation is the leading non-immunologic

132 suggest that more widespread application of pancreas transplantation is warranted.

133 m of this study was to assess whether kidney-pancreas transplantation (KPT) compromises the prognosis

134 mia and apparent insulin insensitivity after pancreas transplantation may be due to increased less po

135 high risk and candidates for combined kidney-pancreas transplantation may be monitored more frequentl

136 hough uncommon, intestinal obstruction after pancreas transplantation may have atypical etiologies.

137 ion episode, and interval between kidney and pancreas transplantation more than 1 year.

138 Since the introduction of pancreas transplantation more than 40 years ago, efforts

139 om organ donors considered inappropriate for pancreas transplantations must be evaluated.

140 Therefore, in the context of islet or pancreas transplantation, newly transplanted beta-cells

141 Pancreas transplantation normalized only insulin-mediate

142 e retrospectively investigated the impact of pancreas transplantation on cardiovascular disease risk

143 To assess the effect of pancreas transplantation on free fatty acid (FFA) and gl

144 n patients with long-standing T1D via kidney-pancreas transplantation or in diabetic mice by treatmen

145 creased to 134/77 mm Hg 1 month after kidney/pancreas transplantation (P<0.001) and decreased further

146 he main factors limiting potential uptake of pancreas transplantation, particularly in the United Kin

147 , alternative method for obtaining tissue in pancreas transplantation patients with graft dysfunction

148 To assess the long-term outcome of kidney/pancreas transplantation, patients were identified who h

149 All pancreas transplantations performed in our center from J

150 received combined intraperitoneal kidney and pancreas transplantation presented at 16 and 11 months a

151 he results and complications of the first 59 pancreas transplantation procedures performed at one ins

152 e first to evaluate the efficacy of IGL-1 in pancreas transplantation (PT) compared with the Universi

153 BACKGROUND.: Pancreas transplantation (PT) provides the best glycemic

154 Pancreas transplantation (PTX) improves diabetic microva

155 Pancreas transplantation (PTX) improves lipids in patien

156 Reproductive hormone function after pancreas transplantation (PTX) is unknown as it has not

157 We analyzed 30 simultaneous kidney-pancreas transplantations receiving tacrolimus, mycophen

158 ped hypoglycemic clamp studies in successful pancreas transplantation recipients to assess epinephrin

159 Pancreas transplantation remains a major surgery with po

160 oration of hypoglycemic counterregulation by pancreas transplantation remains stable in successful pa

161 Pancreas transplantation remains the gold standard for t

162 egalovirus (CMV) disease after kidney and/or pancreas transplantation remains unclear.

163 Successful pancreas transplantation requires surgical expertise and

164 oration for suspected graft thrombosis after pancreas transplantation resulted in a negative laparoto

165 Successful kidney/pancreas transplantation results in a marked improvement

166 BKVAN) in the setting of simultaneous kidney-pancreas transplantation (SKPT) has been inadequately st

167 Simultaneous cadaver kidney and pancreas transplantation (SPK) and living-donor kidney t

168 2 patients who underwent simultaneous kidney-pancreas transplantation (SPK) between 1993 and 1997 to

169 pancreas transplants (17 simultaneous kidney-pancreas transplantation [SPK], 5 pancreas after kidney

170 ransplantation (KTx) and simultaneous kidney-pancreas transplantation (SPKTx).

171 idney transplantations (SPK) and 56 solitary pancreas transplantations (SPT) performed at the Univers

172 Pancreas transplantation survival (complete insulin inde

173 To improve the physiology of pancreas transplantation, the authors developed a new te

174 At 1 month after kidney/pancreas transplantation, the average number of antihype

175 , in patients undergoing simultaneous kidney/pancreas transplantation, the entity of dissynchronous p

176 ss formation have been well documented after pancreas transplantation, the occurrence of small bowel

177 e insulin independence following solid-organ pancreas transplantation, the secondary complications of

178 ressive agents may allow simultaneous kidney-pancreas transplantation to be performed without antilym

179 Islet transplantation is an alternative to pancreas transplantation to cure type 1 diabetes, but bo

180 niques have improved the success of solitary pancreas transplantations to the point where outcome is

181 t standard technique for simultaneous kidney pancreas transplantation usually involves transplanting

182 The rate of first fracture after kidney-pancreas transplantation was 12.1% per patient year, res

183 Time interval between kidney and pancreas transplantation was 5.9 +/- 3.8 (4.8 [1.6-12.2]

184 al failure who underwent simultaneous kidney-pancreas transplantation was found to have stage IV smal

185 Pancreas transplantation was indicated for patients with

186 Pancreas transplantation was performed by robot-assisted

187 Pancreas transplantation was performed using systemic ve

188 ologic imaging, and greater understanding of pancreas transplantation, we hypothesized that ED could

189 the first 3 months after simultaneous kidney-pancreas transplantation were 15-20 ng/ml.

190 Changes in RIs after pancreas transplantation were a poor indicator of acute

191 ive cell transfer and vascularized segmental pancreas transplantation were performed in mice.

192 In the study period, 1276 pancreas transplantations were included.

193 nd December 1, 1998, 147 simultaneous kidney/pancreas transplantations were performed at our center.

194 From July 4, 1994 until April 30, 1998, 147 pancreas transplantations were performed in 141 patients

195 Between 1976 and 2008, 569 pancreas transplantations were performed in Lyon and Gen

196 In the study period, 349 pancreas transplantations were performed.

197 ted hypotension is particularly important in pancreas transplantation where venous thrombosis is a ma

198 assessed, nor has it been determined whether pancreas transplantation, which not only obviates hypogl

199 n norepinephrine response was observed after pancreas transplantation, while glucagon responses to hy

200 excluded, as were those listed for solitary pancreas transplantation who had a serum creatinine leve

201 lent mid-term patient and graft survival for pancreas transplantation with acceptable complication ra

202 All patients underwent whole organ pancreas transplantation with bladder drainage and recei

203 l patients who underwent simultaneous kidney-pancreas transplantation with bladder drainage at our ce

204 Combining cadaver pancreas transplantation with living-donor kidney transp

205 omic function follows both kidney and kidney-pancreas transplantation with more pronounced improvemen

206 eir pancreas graft after simultaneous kidney-pancreas transplantation with P-E drainage underwent pan

207 Eighteen patients underwent pancreas transplantation with portal-enteric (P-E) drain

208 results suggest that simultaneous kidney and pancreas transplantation with SE or PE drainage can be p

209 University of Wisconsin performs all pancreas transplantations with enteric drainage of exocr

210 he efficacy, risks, and costs of whole-organ pancreas transplantation (WOP) with the costs of isolate

211 entation of immunosuppression at the time of pancreas transplantation would protect the recipient fro